- Stocks
- Healthcare
- NASDAQ: IRWD

Price (delayed)

$10.99

Market cap

$1.78B

P/E Ratio

12.21

Dividend/share

N/A

EPS

$0.9

Enterprise value

$1.81B

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Website: https://www.ironwoodpharma.com/

The quick ratio has surged by 86% year-on-year and by 47% since the previous quarter

The company's equity has surged by 76% QoQ

IRWD's revenue is down by 9% YoY but it is up by 2.3% QoQ

Ironwood Pharmaceuticals's gross profit has decreased by 4.9% YoY but it has increased by 2.9% QoQ

IRWD's debt is up by 4% year-on-year

What are the main financial stats of IRWD

Market
Valuations
Earnings

Shares outstanding

161.97M

Market cap

$1.78B

Enterprise value

$1.81B

Price to earnings (P/E)

12.21

Price to book (P/B)

16.05

Price to sales (P/S)

4.44

EV/EBIT

10.28

EV/EBITDA

10.09

EV/Sales

4.54

Revenue

$398.43M

EBIT

$175.76M

EBITDA

$179.05M

Free cash flow

$198.52M

Per share
Balance sheet
Liquidity

EPS

$0.9

Free cash flow per share

$1.23

Book value per share

$0.68

Revenue per share

$2.48

TBVPS

$3.72

Total assets

$599.34M

Total liabilities

$489.15M

Debt

$467.06M

Equity

$110.19M

Working capital

$514.64M

Debt to equity

4.24

Current ratio

22.8

Quick ratio

23.34

Net debt/EBITDA

0.15

Margins
Efficiency
Dividend

EBITDA margin

44.9%

Gross margin

99.8%

Net margin

35.8%

Operating margin

44%

Return on assets

27.3%

Return on equity

402.5%

Return on invested capital

28.6%

Return on capital employed

30.5%

Return on sales

44.1%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Ironwood Pharmaceuticals stock price performed over time

Intraday

0%

1 week

1.48%

1 month

7.85%

1 year

2.14%

YTD

-3.51%

QTD

-1.7%

How have Ironwood Pharmaceuticals's revenue and profit performed over time

Revenue

$398.43M

Gross profit

$397.53M

Operating income

$175.11M

Net income

$142.76M

Gross margin

99.8%

Net margin

35.8%

IRWD's net margin has surged by 87% year-on-year and by 31% since the previous quarter

The net income has soared by 70% YoY and by 34% from the previous quarter

IRWD's operating margin is up by 29% year-on-year and by 20% since the previous quarter

The operating income has increased by 23% from the previous quarter and by 17% YoY

What is Ironwood Pharmaceuticals's growth rate over time

What is Ironwood Pharmaceuticals stock price valuation

P/E

12.21

P/B

16.05

P/S

4.44

EV/EBIT

10.28

EV/EBITDA

10.09

EV/Sales

4.54

The EPS has surged by 67% year-on-year and by 34% since the previous quarter

IRWD's P/E is 17% below its last 4 quarters average of 14.7

The company's equity has surged by 76% QoQ

IRWD's P/S is 32% below its 5-year quarterly average of 6.5 but 6% above its last 4 quarters average of 4.2

IRWD's revenue is down by 9% YoY but it is up by 2.3% QoQ

How efficient is Ironwood Pharmaceuticals business performance

The return on sales has surged by 64% year-on-year and by 24% since the previous quarter

Ironwood Pharmaceuticals's ROIC has increased by 44% YoY and by 27% from the previous quarter

Ironwood Pharmaceuticals's return on assets has increased by 22% QoQ and by 18% YoY

What is IRWD's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for IRWD.

How did Ironwood Pharmaceuticals financials performed over time

The total assets is 23% more than the total liabilities

Ironwood Pharmaceuticals's current ratio has soared by 88% YoY and by 48% from the previous quarter

The quick ratio has surged by 86% year-on-year and by 47% since the previous quarter

The company's debt to equity has surged by 168% YoY but it fell by 43% QoQ

The company's equity has surged by 76% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.